MGS Launches A.i.r. Platform

MGS, a provider of end-to-end healthcare solutions, has launched the A.i.r. Platform, a customizable auto-injector platform designed to meet the diverse needs of patients, pharmaceutical innovators and healthcare providers.

Built around an adaptable core engine (with patents pending) that can be integrated into multiple device formats, the Auto-injector Reimagined (A.i.r.) Platform empowers companies to bring ownable, patient-centric drug delivery devices to market faster and more efficiently. Available in customizable fill volumes ranging from 0.3 to 2.25 mL, A.i.r. supports flexible development paths to meet a wide range of therapeutic, usability and brand requirements. The platform enables extreme customization across form, function and aesthetics – enhancing performance through patient-friendly features. Brand owners can tailor each device to align closely with their drug and brand identity, delivering a distinct patient experience and meaningful product differentiation.

The platform was developed using insights from 14 therapeutic areas, reflecting input from clinicians, patients, regulatory feedback and FDA data. The result is a highly customizable device that addresses common issues seen with existing injectors, including incomplete injections, activation failures and usability barriers. Designed to accommodate a range of development needs – including programs that require lower manufacturing volumes – A.i.r gives Pharma companies the flexibility to tailor devices across a broad set of features and functions, including:

• Adjustable injection time.
• Customizable fill volumes and activation profiles.
• Compatibility with a variety of drug viscosities.
• Specification of cap release.
• Brand identification.
• Patient usability (form, materials, window size, grip).

With just seven plastic parts and two springs, the A.i.r. Platform is intentionally engineered for simplicity, reducing the risk of failure, enabling faster and more efficient assembly and supporting sustainable product goals.

“The A.i.r. Platform is the result of years of discovery, engineering and collaborative design and development expertise,” said Martin Hoier Thomsen, Senior Development Engineer and Project Manager at MGS. “It was created to give customers access to more customization, advanced features and greater flexibility to meet a diverse range of patient needs, including pediatric-focused designs and solutions for users with limited dexterity due to chronic conditions. Pharma companies with drugs in development that require unique delivery solutions can avoid starting from scratch and save years of development time to reduce time to clinic.”